VITIELLO, PAOLA
VITIELLO, PAOLA
Universita' degli Studi di MILANO
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation
2020 V. Di Cristo, F. Adorni, R. Maserati, M. Annovazzi Lodi, G. Bruno, P. Maggi, A. Volpe, P. Vitiello, C. Abeli, S. Bonora, M. Ferrara, M.V. Cossu, M.L. Oreni, E. Colella, S. Rusconi
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides
2016 A. Di Biagio, N. Riccardi, L. Taramasso, A. Capetti, G. Cenderello, A. Signori, P. Vitiello, M. Guerra, G.V. de Socio, G. Cassola, T. Quirino, C. Viscoli
Levofloxacin-induced seizures in a patient without predisposing risk factors : the impact of pharmacogenetics
2013 C. Gervasoni, D. Cattaneo, F.S. Falvella, P. Vitiello, S. Cheli, L. Milazzo, E. Clementi, A. Riva
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
2013 S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Focà, A. Capetti, P. Meraviglia, C. Abeli, S. Bonora, M. D'Annunzio, A. Di Biagio, M. Di Pietro, L. Butini, G. Orofino, M. Colafigli, G. D'Ettorre, D. Francisci, G. Parruti, A. Soria, A.R. Buonomini, C. Tommasi, S. Mosti, F. Bai, S. Di Nardo Stuppino, M. Morosi, M. Montano, P. Tau, E. Merlini, G. Marchetti
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database
2013 S. Rusconi, P. Vitiello, F. Adorni, B. Bruzzone, A. De Luca, V. Micheli, P. Meraviglia, R. Maserati, M. Di Pietro, G. Colao, G. Penco, A. Di Biagio, G. Punzi, L. Monno, M. Zazzi
Maraviroc : un inibitore del co-recettore CCR5 con un unico profilo di efficacia e tollerabilita’ in diversi scenari clinici dell'infezione da HIV-1
2012 S. Rusconi, E. Colella, P. Vitiello
Does GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results
2011 M. Ortu, P. Vitiello, F. Adorni, R. Rossotti, P. Di Vincenzo, O. Viganò, M. Galli, S. Rusconi
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens
2011 D. Gonzalez de Requena, S. Bonora, O. Viganò, A. Calcagno, C. Cometto, A. D'Avolio, L. Baietto, V. Ghisetti, S. Magnani, S. Ferramosca, P. Vitiello, M. Galli, S. Rusconi, G. Di Perri
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA)
2010 P. Di Vincenzo, S. Rusconi, F. Adorni, P. Vitiello, F. Maggiolo, D. Francisci, A. Di Biagio, L. Monno, A. Antinori, E. Boeri, G. Punzi, C. F. Perno, A. Callegaro, B. Bruzzone, M. Zazzi on behalf of the Antiretroviral Resistance Cohort Analysis (ARCA) Collaborative Group
Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART
2010 S. Rusconi, P. Vitiello, F. Adorni, S. Ferramosca, E. Focà, A. Capetti, P. Meraviglia, T. Quirino, S. Bonora, M. D’Annunzio, A. Di Biagio, M. Di Pietro, L. Butini, G. Orofino, M. Colafigli, V. Vullo, D. Francisci, M. Andreoni, E. Merlini, G. Marchetti
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
2010 S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Focà, A.F. Capetti, P. Meraviglia, C. Abeli, S. Bonora, M. D’Annunzio, A. Di Biagio, A. Di Pietro, L. Butini, G. Orofino, S. Farina, G. D’Ettorre, D. Francisci, A. Soria, A.R. Buonomini, C. Tommasi, M.P. Trotta, M. Capasso, E. Merlini, G.C. Marchetti
Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature
2010 F. Croce, P. Vitiello, A. DALLA PRIA, A. Riva, M. Galli, S. Antinori
Determinants of virological response to raltegravir (RAL)-containing regimens and prevalence of RAL-resistance associated mutations at failure in ARCA
2010 S. Rusconi, P. Vitiello, F. Adorni, B. Bruzzone, A. De Luca, V. Micheli, P. Meraviglia, R. Maserati, M. Di Pietro, G. Colao, G. Penco, A. Di Biagio, G. Punzi, L. Monno, M. Zazzi on behalf of the ARCA Collaborative Group
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
2008 B. Vergani, M. Lo Cicero, O. Viganò, F. Sirianni, S. Ferramosca, P. Vitiello, P. Di Vincenzo, M.P. De Pasquale, M. Galli, S. Rusconi